Literature DB >> 16437151

Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma.

C Fauriat, F Mallet, D Olive, R T Costello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16437151     DOI： 10.1038/sj.leu.2404096

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  44 in total

Review 1.  Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Tim Luetkens; Djordje Atanackovic
Journal:  Oncoimmunology       Date:  2017-03-28       Impact factor: 8.110

Review 2.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

3.  The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Authors:  Subhashis Sarkar; Sachin K S Chauhan; John Daly; Alessandro Natoni; Heather Fairfield; Robert Henderson; Emma Nolan; Dawn Swan; Jinsong Hu; Michaela R Reagan; Michael O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  2020-01-09       Impact factor: 6.968

4.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 5.  Natural killer cell lines in tumor immunotherapy.

Authors:  Min Cheng; Jian Zhang; Wen Jiang; Yongyan Chen; Zhigang Tian
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

6.  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Authors:  Vladimir Jurisic; Tatjana Srdic; Gordana Konjevic; Olivera Markovic; Milica Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.

Authors:  Bianca Altvater; Silke Landmeier; Sibylle Pscherer; Jaane Temme; Katharina Schweer; Sareetha Kailayangiri; Dario Campana; Heribert Juergens; Martin Pule; Claudia Rossig
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

Review 8.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

9.  Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy.

Authors:  Régis T Costello; Anne Boehrer; Carole Sanchez; Delphine Mercier; Céline Baier; Thérèse Le Treut; Gérard Sébahoun
Journal:  Immunology       Date:  2013-07       Impact factor: 7.397

Review 10.  The challenges of checkpoint inhibition in the treatment of multiple myeloma.

Authors:  Barry Paul; Shuqi Kang; Zhihong Zheng; Yubin Kang
Journal:  Cell Immunol       Date:  2018-10-13       Impact factor: 4.868
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.